A carregar...
Publicação
Pfizer & Wyeth: acquiring to survive, rather than to grow
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 587.78 KB | Adobe PDF | |||
| 1.96 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This case focus on the strategy that motivated Pfizer to go, by 2009, through the
acquisition of Wyeth. Beyond the strategic reasons, this case will discuss the financial
implications of the deal jointly analysing the impact on financial key ratios for Pfizer’s
investors. As the historical Pfizer’s portfolio of acquisitions is considerably extended, its
investors are left with questions about the realization of the synergies announced as well as the
ability to integrate Wyeth’s business in such a tough period.
Descrição
Palavras-chave
Mergers & acquisitions Corporate finance Deal financing